Cyclic and individualized administration of gonadotropin-releasing hormone agonists plus progestogens: An alternative protocol for contraception

References

• Hall J. G., Pauli R. M., Wilson K. M. Maternal and fetal sequelae of anticoagulation during pregnancy. Am. J. Med. 1980; 68: 122–40
   PubMed Web of Science ®Google Scholar
• Proempeler H., Wieacker P., Hillemanns H. G., Breckwoldt M. Einsatz von Gn-RH-analoga bei markumarisierten Patientinnen zur Antikonzeption und Prophylaxe von lebensbed-rohlichen Ovulationsblutungen. Geburtsh. Frauen-heilk. 1988; 48: 588–96
   PubMedGoogle Scholar
• Nillius S. J., Bergquist G., Wiole L. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue - a new approach to birth control?. Contraception 1978; 17: 537–45
   Web of Science ®Google Scholar
• Bergquist C., Nillius S. J., Wide L. Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist. Contraception 1979; 19: 497–506
   PubMed Web of Science ®Google Scholar
• Schmidt-Gollwitzer M., Hardt W., Schmidt-Gollwitzer K., Nevinny-Stickel J. Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?. Contraception 1981; 23: 187–95
   PubMed Web of Science ®Google Scholar
• Bergquist C., Nillius S. J., Wide L. Peptide contraception in women. Inhibition of ovulation by chronic intranasal LRH agonist therapy. UpsalaJ. Med. So'. 1984; 89: 99–106
   PubMed Web of Science ®Google Scholar
• Hardt W., Schmidt-Gollwitzer K., Nevinny-Stickel J., Schmidt-Gollwitzer M. Fortschritte in der kontraceptiven Anwendung des LH-RH-Agonisten Buserelin: discontinuerliche Medikation mit gestagen induzierter Abbruch-blutung. Geburtsh. Frauenheilk. 1982; 42: 874–7
   PubMedGoogle Scholar
• Lemay A., Faure N., Lobrie F., Fazekas A. T. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone-agonist dosing in combination with gestagen-induced bleeding. Fertil. Steril 1985; 43: 868–77
   PubMed Web of Science ®Google Scholar
• Lemay A., Faure N., Bastide A. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach. Fertil. Steril 1987; 47: 60–6
   PubMed Web of Science ®Google Scholar
• Kuhl H., Jung C., Taubert H.-D. Contraception with an LH-RH agonist: effect of gonadotropin and steroid secretion patterns. Clin. Endocrinol. 1984; 21: 179–84
   PubMed Web of Science ®Google Scholar
• Pietzsch V., Kuhl H. Kontraception durch zyklische Gabe von Buserelin und Gesta-genen: Zunahme der Serumkonzentrationen von Testosteron und freiem Testosteron. Geburtsh. Frauenheilk. 1991; 51: 819–23
   PubMedGoogle Scholar
• Wieacker P., Breckwoldt M., Greif M., Geisthoevel F. Antikonzeption durch zyclische Behandlung mit Buserelin und Progesteron. Geburtsh. Frauenheilk. 1991; 51: 135–9
   PubMedGoogle Scholar
• Hackeloer B. J., Fleming R., Robinson H. P., Adam A. H., Coutts J. R. T. Correlation of ultrasonic and endocrinologic assessment of human follicular development. Am. J. Obstet. Gynecol. 1979; 135: 122–31
   PubMed Web of Science ®Google Scholar
• Hardt N., Schmidt-Gollwitzer M., von der Ohe M., Nevinny-Stickel J. The influence of long-term medication with LH-RH analogue buserelin in the regulation of the menstrual cycle. Geburtsh. Frauenheilk. 1981; 41: 791–8
   PubMed Web of Science ®Google Scholar
• Soules M. R., Clifton D. K., Steiner R. A., Cohen N. L., Bremner W. J. Gona-dotropin-releasing-hormone induced changes in testosterone secretion in normal women. Fertil. Steril 1987; 48: 423–7
   PubMed Web of Science ®Google Scholar
• Henzl M. R., Corson S., Moghissi K., Buttram V. C., Bergquist C., Jacobson J. Administration of nasal buserelin versus oral dana-zol for endometriosis. A multicenter double-blind comparative clinical trial. N. Engl. J. Med. 1988; 318: 485–91
   PubMed Web of Science ®Google Scholar
• Lemay A., Sandow J., Bureau M. Prevention of follicular maturation in endometriosis by subcutaneous infusion of luteinizing hormone-releasing hormone agonist started in luteal phase. Fertil. Steril 1988; 49: 410–17
   PubMed Web of Science ®Google Scholar
• Devogelaer J. P., NagantdeDeuxchaismes C., Donnez J. Differential action of the LHRH agonist buserelin on trabecular and cortical bone. LHRH Analogues in Gynaecology, B. Runnebaum, I. Brosens, H. S. Jacobs. Parthenon Publishing Group, CarnforthUK 1990; 195–8
   Google Scholar
• Erickson L. D., Ory S. J. GnRH analogues in the treatment of endometriosis. Obstet. Gynecol. N. Am. 1989; 16: 123–45
   PubMed Web of Science ®Google Scholar
• Loumaye E., Vankrieken L., Depreester S., Psatti I., De Cooman S., Thomas K. Hormonal changes induced by short-term administration of a gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development. Fertil. SteriL 1989; 51: 105–11
   PubMed Web of Science ®Google Scholar
• Urbancsek J., Rabe T., Goer U., Schultz B., Grunwald K., Papp Z., Runnebaum B. Wirkung der GnRH-Analogous Buserelin auf die Serum-Spiegel von Sexual-hormonen in Abhaengigkeit von Behandlungsbeginn und Be-handlungsdauer. Geburtsh. Frauenheilk. 1991; 51: 617–25
   PubMedGoogle Scholar
• Lauritzen C., Lehmann W.-D. Besonderheiten der Wirkungen der einzelnen Gestagene auf Morphologie und Funktion des Genitaltraktes. A. Beim Menschen. Handbook of Experimental Pharmacology, Band XXII/2, Die Gestagene, E. Diczfalusy, C. Lavritzen. Springer-Verlag, Berlin, New York 1969; 1–39
   Google Scholar
• Sandow J., Froser H. M., Geisthoevel K. Pharmacology and experimental basis of therapy with LHRH agonists in women. Gonadotropin Down-Regulation in Gynecological Practice. Progress in Clinical and Biological Research, R. Rolland, D. R. Chadha, W. N. P. Willemsen. Allan Liss, New York 1986; 25: 1–27
   Google Scholar
• Chang R. J., Laufer L. R., Meldrum D. R., DeFazio J., Lu J. K., Vale W., Riviez J. E., Judd H. L. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J. Clin. Endocrinol. Metab. 1983; 56: 897–902
   PubMed Web of Science ®Google Scholar
• Lemay A., Maheux R., Faure N., Jean C., Fazekas A. T. A. Reversible hypogonadism induced by luteinizing hormone-releasing hormone (LH-RH) for endometriosis. Fertil. Steril. 1984; 41: 863–71
   PubMed Web of Science ®Google Scholar
• Palermo R., Amadeo G., Navot D., Rosenwaks Z., Gittadini E. Concomitant gonadotropin-releasing hormone agonist and menotro-pin treatment for the synchronized induction of multiple follicles. Fertil. Steril 1988; 49: 290–5
   PubMed Web of Science ®Google Scholar